



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

December 6, 2010

Dr. Friedhelm Blobel, Ph.D.  
Chief Executive Officer  
SciClone Pharmaceuticals, Inc.  
950 Tower Lane, Suite 900  
Foster City, CA 94404 [Company Name and Address]

**Re: SciClone Pharmaceuticals, Inc.**  
**Form 10-K for the year ended December 31, 2009**  
**Definitive Proxy Statement on Schedule 14A filed April 30, 2010**  
**Form 10-K/A for the year ended December 31, 2009**  
**File No. 000-19825**

Dear Dr. Blobel:

We have completed our review of your filings and do not have any further comments at this time.

Sincerely,

Assistant Director  
Jeffrey Riedler

cc: Howard Clowes  
DLA Piper LLP  
555 Mission Street, Suite 2400  
San Francisco, CA 94105